| | ||||||||||
| 1 | INN | Class | Route (list) | PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693) | Primary Target and PDB code of Protein-Drug complex | Targets from DrugCentral | Links | |||
| PALBOCICLIB
| PALBOCICLIB | ANTINEOPLASTIC | ORAL | Tmax 9 HOUR F 46 PERCENT VD 2583 LITER PPB 85 PERCENT Cl 63.1 LITER / HOUR HT 29 HOUR SOLUBILITY ABOVE PH4 THE SOLUBILITY REDUCES SIGNIFICANTLY | CYCLIN-DEPENDENT KINASE (CDK) 4 CYCLIN-DEPENDENT KINASE (CDK) 6 PDB 2EUF (X-RAY STRUCTURE OF HUMAN CDK6-VCYCLIN IN COMPLEX WITH THE INHIBITOR PD0332991) LIGAND CODE = LQQ (link to the list of PDB complexes) Download experimental 3D coordinates of LQQ with added hydrogens | CDK4/CYCLIN D1 INHIBITOR CHEMBL1907601 CYCLIN-DEPENDENT KINASE 4/CYCLIN D1 P11802 CYCLIN-DEPENDENT KINASE 4 HOMO SAPIENS ENZYME KINASE PROTEIN KINASE CMGC | EMA | |||
